• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Ubrogepant is safe and effective for acute treatment of migraine prodrome

byNeel MistryandTeddy Guo
January 25, 2024
in Chronic Disease, Neurology
Reading Time: 2 mins read
Migraine collage: a woman resting with eyes closed and a finger at her temple, a zigzag aura, window blinds and sunglasses
Share on FacebookShare on TwitterShare on LinkedIn

1. Absence of moderate or severe headache 24 hours following administration of treatment drug was significantly greater among patients with migraine attacks that were treated with ubrogepant during the prodrome phase.

2. Adverse events were slightly more frequent in the ubrogepant group versus placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ubrogepant, a calcitonin gene-related peptide (cGRP) receptor antagonist, is approved for acute migraine treatment. However, its use during the prodromal phase to reduce the frequency of subsequent migraine headaches is not well understood. This phase 3 randomized controlled trial aimed to evaluate the safety, efficacy, and tolerability of ubrogepant when administered during the prodrome phase of a migraine attack. The primary outcome was the absence of moderate or severe headache within 24 hours after drug use, while the key secondary outcome was the absence of any headache. According to study results, ubrogepant demonstrated effectiveness, with a significantly higher rate of headache absence compared to placebo. This study was strengthened by individuals of all age groups with a chronic history of migraines, thus adding to the validity of the findings.

Click to read the study in The Lancet

Relevant Reading: Ubrogepant for the Treatment of Migraine

RELATED REPORTS

Zavegepant (Zavzpret) may be effective for the management of migraine symptoms in Asian adults

Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines

In-depth [randomized-controlled trial]: Between Aug 21, 2020, and Apr 19, 2022, 1087 patients were screened for eligibility across 75 research centers in the USA. Included were patients ≥ 18 years with ≥ 1-year history of migraine and 2-8 migraine attacks per month. Altogether, 466 patients (239 in placebo then ubrogepant 100 mg and 227 in ubrogepant 100 mg than placebo) were included in the final analysis. The primary outcome of absence of moderate or severe headache within 24 hours was significantly higher after ubrogepant administration compared to placebo (46% vs. 29%, odds ratio [OR] 2.09, 95% confidence interval [CI] 1.63-2.69, p<0.0001). Furthermore, adverse events were reported in both groups but occurred more frequently with ubrogepant than placebo (17% vs. 12%). Findings from this study suggest that ubrogepant is both safe and effective for the acute treatment of migraine attacks.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: headachemigrainemigraine prodromemigraine with auramigrane without auraneurologyubrogepant
Previous Post

#VisualAbstract: Selective early treatment of patent ductus arteriosus with ibuprofen in preterm infants improves short-term outcomes

Next Post

Obsessive-compulsive disorder and risk of all-cause and cause-specific mortality

RelatedReports

Migraine collage: a woman resting with eyes closed and a finger at her temple, a zigzag aura, window blinds and sunglasses
Chronic Disease

Zavegepant (Zavzpret) may be effective for the management of migraine symptoms in Asian adults

November 6, 2026
A woman experiencing a migraine, with visual representation of signaling pathways and a pill nearby, suggesting treatment with Rimegepant.
Chronic Disease

Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines

October 6, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Chronic Disease

One in four National Football League (NFL) players who died between 2016-2021 had evidence of chronic traumatic encephalopathy

August 27, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Chronic Disease

Brain-predicted age difference may reliably predict dementia progression

August 19, 2026
Next Post
Mental health collage: a calm young woman with her eyes closed, a sleeping dog and an open notebook with a pencil

Obsessive-compulsive disorder and risk of all-cause and cause-specific mortality

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Increased Mortality From COVID-19 In Severe Mental Illness Patients With Comorbidities and Those of Black Race

#VisualAbstract: Testosterone Treatment Does Not Reduce the Incidence of Fractures in Men with Hypogonadism

#VisualAbstract: Testosterone Treatment Does Not Reduce the Incidence of Fractures in Men with Hypogonadism

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.